Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes

S.G. Swinnen; F.J. Snoek; M.P. Dain; J.H. de Vries; J. Hoekstra-Slikkerveer; F. Holleman

doi:10.1089/dia.2009.0044

Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes

S.G. Swinnen, F.J. Snoek, M.P. Dain, J.H. de Vries, J. Hoekstra-Slikkerveer, F. Holleman

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	739-743
Journal	Diabetes Technology and Therapeutics
Volume	11
Issue number	11
DOIs	https://doi.org/10.1089/dia.2009.0044
Publication status	Published - 2009

Access to Document

10.1089/dia.2009.0044

Cite this

Swinnen, S. G., Snoek, F. J., Dain, M. P., de Vries, J. H., Hoekstra-Slikkerveer, J., & Holleman, F. (2009). Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technology and Therapeutics, 11(11), 739-743. https://doi.org/10.1089/dia.2009.0044

@article{b9fde94f122a453faa5272702e67c9ea,

title = "Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes",

author = "S.G. Swinnen and F.J. Snoek and M.P. Dain and {de Vries}, J.H. and J. Hoekstra-Slikkerveer and F. Holleman",

year = "2009",

doi = "10.1089/dia.2009.0044",

language = "Undefined/Unknown",

volume = "11",

pages = "739--743",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

number = "11",

}

Swinnen, SG, Snoek, FJ, Dain, MP, de Vries, JH, Hoekstra-Slikkerveer, J & Holleman, F 2009, 'Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes', Diabetes Technology and Therapeutics, vol. 11, no. 11, pp. 739-743. https://doi.org/10.1089/dia.2009.0044

Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. / Swinnen, S.G.; Snoek, F.J.; Dain, M.P. et al.

In: Diabetes Technology and Therapeutics, Vol. 11, No. 11, 2009, p. 739-743.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes

AU - Swinnen, S.G.

AU - Snoek, F.J.

AU - Dain, M.P.

AU - de Vries, J.H.

AU - Hoekstra-Slikkerveer, J.

AU - Holleman, F.

PY - 2009

Y1 - 2009

U2 - 10.1089/dia.2009.0044

DO - 10.1089/dia.2009.0044

M3 - Article

C2 - 19905891

VL - 11

SP - 739

EP - 743

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 11

ER -

Swinnen SG, Snoek FJ, Dain MP, de Vries JH, Hoekstra-Slikkerveer J, Holleman F. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technology and Therapeutics. 2009;11(11):739-743. doi: 10.1089/dia.2009.0044